Special Issue Archive - Oncology Practice Management

Skip to main content

Latest Special Issue

$Quality Improvement Strategies to Optimize Outpatient Step-Up Dosing for Elranatamab in Relapsed/Refractory Multiple Myeloma$

Clinical Trials to Clinical Practice

Quality Improvement Strategies to Optimize Outpatient Step-Up Dosing for Elranatamab in Relapsed/Refractory Multiple Myeloma

In this publication, clinical experts from Massachusetts General Hospital (MGH) examine quality improvement (QI) and quality assurance (QA) strategies that support the safe and effective outpatient administration of bispecific antibodies such as elranatamab in patients with relapsed/refractory multiple myeloma.

Special Issues Archive

Quality Improvement Strategies to Optimize Outpatient Step-Up Dosing for Elranatamab in Relapsed/Refractory Multiple Myeloma

Pirtobrutinib in Covalent BTKi-Treated Patients With CLL/SLL: Translating Clinical Trial Insights Into Real-World Practice

2026 Oncology Guide to Patient Support Services

The Evolution of Abemaciclib Clinical Trial Data for the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer

Identification and Treatment of Patients With Hormone Receptor–Positive, HER2-Negative Early Breast Cancer at High Risk of Recurrence: monarchE Study Long-Term Outcomes

Pirtobrutinib in Pretreated Patients With CLL/SLL: Applying Lessons From Clinical Trials to Clinical Practice

Best Practices in Ovarian Function Suppression in Breast Cancer

2023 Year in Review: Cholangiocarcinoma

Clinical Trials to Clinical Practice: GI Cancer Edition

Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

2022 Year in Review: Multiple Myeloma

2022 Year in Review: Cholangiocarcinoma

Faculty Perspectives: Optimizing Clinical Outcomes and Value-Based Management in Multiple Myeloma—The Role of Isatuximab

Current Approach to the Disease Journey of Patients with Relapsed or Refractory Follicular Lymphoma: Focus on the Key Manifestations, Risk Stratification, and Management Patterns

Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC

2022 Midyear Review: Non–Small-Cell Lung Cancer

Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management

ASK THE EXPERT: First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy

2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments

2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments

2022 Oncology Biosimilar Guide to Patient Support Services

2022 Breast Cancer Guide to Patient Support Services

Looking for more?

Browse the Digital Archive

2014 - Current

Back to Top